99 related articles for article (PubMed ID: 15661273)
41. Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers.
Löfström B; Backlin C; Sundström C; Hellström-Lindberg E; Ekbom A; Lundberg IE
Rheumatology (Oxford); 2009 Oct; 48(10):1222-6. PubMed ID: 19608725
[TBL] [Abstract][Full Text] [Related]
42. High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia.
Xu LP; Luo XH; Chang YJ; Liu DH; Liu KY; Chen YH; Huang XJ
Ann Hematol; 2009 Oct; 88(10):1015-24. PubMed ID: 19319533
[TBL] [Abstract][Full Text] [Related]
43. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
Radojkovic M; Ristic S; Pavlovic S; Colovic M
Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
[TBL] [Abstract][Full Text] [Related]
44. Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion.
Jootar S; Pornprasertsud N; Petvises S; Rerkamnuaychoke B; Disthabanchong S; Pakakasama S; Ungkanont A; Hongeng S
Leuk Res; 2006 Dec; 30(12):1493-8. PubMed ID: 16839603
[TBL] [Abstract][Full Text] [Related]
45. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
Simon W; Segel GB; Lichtman MA
Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
[TBL] [Abstract][Full Text] [Related]
46. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis.
Soupir CP; Vergilio JA; Dal Cin P; Muzikansky A; Kantarjian H; Jones D; Hasserjian RP
Am J Clin Pathol; 2007 Apr; 127(4):642-50. PubMed ID: 17369142
[TBL] [Abstract][Full Text] [Related]
47. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
Gadzicki D; von Neuhoff N; Steinemann D; Just M; Büsche G; Kreipe H; Wilkens L; Schlegelberger B
Cancer Genet Cytogenet; 2005 Jun; 159(2):164-7. PubMed ID: 15899391
[TBL] [Abstract][Full Text] [Related]
48. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.
Greiner J; Schmitt M
Eur J Haematol; 2008 Jun; 80(6):461-8. PubMed ID: 18284627
[TBL] [Abstract][Full Text] [Related]
49. Case report and literature review: a rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia.
Bhagavathi S; Borromeo V; Desai H; Crisan D
Ann Clin Lab Sci; 2008; 38(4):405-9. PubMed ID: 18988937
[TBL] [Abstract][Full Text] [Related]
50. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
[TBL] [Abstract][Full Text] [Related]
51. Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients.
Ramanarayanan J; Dunford LM; Baer MR; Sait SN; Lawrence W; McCarthy PL
Leuk Res; 2006 Jun; 30(6):701-5. PubMed ID: 16330096
[TBL] [Abstract][Full Text] [Related]
52. [The application of fluorescence in situ hybridization in detecting chronic myeloid leukemia].
Qiu HR; Miao KR; Wang R; Qiao C; Zhang JF; Zhang SJ; Qian SX; Xu W; Li JY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Apr; 26(2):207-10. PubMed ID: 19350518
[TBL] [Abstract][Full Text] [Related]
53. Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
Lichtman MA
Oncologist; 2008 Jun; 13(6):645-54. PubMed ID: 18586919
[TBL] [Abstract][Full Text] [Related]
54. Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse.
Ringhoffer M; Harsdorf Sv; Schmitt M; Wiesneth M; Zenz T; Stilgenbauer S; Greiner J; Döhner K; Marx M; Döhner H; Bunjes D
Br J Haematol; 2007 Jan; 136(1):127-30. PubMed ID: 17222200
[TBL] [Abstract][Full Text] [Related]
55. Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patients with chronic myeloid leukemia.
Zhao ZG; Li WM; Chen ZC; You Y; Zou P
Immunol Invest; 2008; 37(7):726-39. PubMed ID: 18821219
[TBL] [Abstract][Full Text] [Related]
56. [Chronic myelomonocytic leukemia and esophageal cancer developed in a renal allograft recipient].
Shima T; Oku N; Goto H; Inaba T; Murakami S; Itoh K; Fujita N; Shimazaki C; Misawa S; Nakagawa M
Rinsho Ketsueki; 1993 Jul; 34(7):842-6. PubMed ID: 8360988
[TBL] [Abstract][Full Text] [Related]
57. Pediatric secondary chronic myeloid leukemia following cardiac transplantation for anthracycline-induced cardiomyopathy.
Menon NM; Katsanis E; Khalpey Z; Whitlow P
Pediatr Blood Cancer; 2015 Jan; 62(1):166-8. PubMed ID: 25175922
[TBL] [Abstract][Full Text] [Related]
58. Chronic granulocytic leukemia after renal transplantation.
Kirchner KA; Files JC; Didlake R; Raju S; Krueger RP
Arch Intern Med; 1983 Oct; 143(10):1984-7. PubMed ID: 6354125
[TBL] [Abstract][Full Text] [Related]
59. Imputability of Azathioprine in the Occurrence of Chronic Myeloid Leukemia in Crohn's Disease: An Exceptional Case Report.
Zaimi Y; Bouksir C; Ayadi S; Ayari M; Ksontini FL
Curr Drug Saf; 2023; 18(4):596-598. PubMed ID: 35676842
[TBL] [Abstract][Full Text] [Related]
60. Elevated incidence of chronic myeloid leukaemia in immunosuppressed solid organ transplant recipients.
Dhanarajan A; Hsu JW; le Coutre P; Wingard JR; Chang M; Norkin M
Br J Haematol; 2014 Aug; 166(4):619-21. PubMed ID: 24697357
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
